Thursday, April 11, 2019, Anaheim, California, 12:15 PM – 1:45 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A 6-Part CNE Symposia Series Held During the ONS 44th Annual Congress

PART 4 — Chronic Lymphocytic Leukemia

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room:
Grand Ballroom E-K (Lobby Level)
11:45 AM – 12:15 PM
Registration and Lunch Buffet

12:15 PM – 1:45 PM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Paul M Barr, MD
Medical Director, Clinical Trials Office
Associate Professor of Medicine
Wilmot Cancer Institute
University of Rochester Medical Center
Rochester, New York

Josie Bazemore, MSN, AGPCNP-BC
Dana-Farber Cancer Institute
Boston, Massachusetts

Nitin Jain, MD
Associate Professor of Medicine
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Lynn Rich, RN, MSN, OCN, BC-ANP
University of Rochester
Wilmot Cancer Institute
Lymphoma Program
Rochester, New York

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by AbbVie Inc, Genentech, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC and Pharmacyclics LLC, an AbbVie Company during the Oncology Nursing Society’s (ONS) 44th Annual Congress, April 11-14, 2019 in Anaheim, California. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
11:45 AM – 12:15 PM – Registration and Lunch Buffet
12:15 PM – 1:45 PM – Educational Program

Module 1: Diagnostic Considerations in the Care of Patients with Chronic Lymphocytic Leukemia (CLL)


  • Incidence of genetic abnormalities in CLL (eg, 17p deletions, TP53 and IGHV gene mutations) and implication for long-term prognosis
  • Indications for observation as opposed to active therapy in asymptomatic patients with newly diagnosed CLL
  • Optimal surveillance for patients with newly diagnosed CLL who elect observation over active therapy
  • Unique supportive care concerns among patients with CLL (monitoring for infections, hypogammaglobulinemia, et cetera)
  • Indications for repeat biomarker assessment in patients with progressive CLL

Module 2: Biological and Clinical Considerations in the Treatment of Newly Diagnosed CLL


  • Commonly employed up-front regimens for younger and older patients with CLL and normal- or high-risk cytogenetics
  • Long-term efficacy outcomes observed in published clinical trials of commonly employed induction regimens (eg, FCR, BR, ibrutinib, obinutuzumab/chemotherapy)
  • Recent FDA approval of obinutuzumab/ibrutinib for patients with treatment-naïve CLL and optimal integration into clinical practice
  • Other recently presented data sets evaluating ibrutinib-based therapy versus standard chemoimmunotherapeutic regimens as first-line treatment for CLL
  • Monitoring for and management of toxicities associated with the use of chemoimmunotherapy or ibrutinib-based regimens in patients with newly diagnosed CLL
  • Emerging data with venetoclax/obinutuzumab in patients with previously untreated CLL and coexisting medical conditions

Module 3: Contemporary Management of Relapsed/Refractory CLL


  • Individualizing the selection and sequencing of therapies in the relapsed/refractory setting based on the induction regimen received, disease-free interval and other clinical and biologic factors
  • Key efficacy and safety findings with venetoclax/rituximab for relapsed/refractory CLL; recent FDA approval of venetoclax for patients without del(17p)
  • Risk of and preemptive measures to prevent tumor lysis syndrome associated with venetoclax
  • Mechanistic similarities and differences between acalabrutinib and ibrutinib; potential effect on clinical outcomes and tolerability
  • Rates of cardiac adverse events (eg, atrial fibrillation, hypertension, bleeding) with acalabrutinib; practical considerations with the use of off-protocol acalabrutinib in CLL, including dosing and management of common side effects (eg, headache)
  • Appropriate integration of idelalisib and duvelisib into current treatment algorithms; recognition, prevention and management of PI3 kinase inhibitor-associated toxicities in patients with relapsed/refractory CLL

Module 4: Novel Agents and Strategies Under Investigation in CLL


  • Early efficacy and safety data with other novel combination approaches (eg, ibrutinib/venetoclax, ibrutinib/FCR, obinutuzumab/ibrutinib/venetoclax) in newly diagnosed and relapsed/refractory CLL
  • Biologic rationale for the evaluation of chimeric antigen receptor T-cell therapies for patients with CLL; available clinical trial results and ongoing studies
  • Other novel agents currently under investigation for CLL

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:

  • Provide patient education to enhance clinical decision-making regarding systemic agents available for the management of chronic lymphocytic leukemia (CLL).
  • Appreciate the contribution of patient performance status and comorbidities, biomarker profile and prior therapeutic exposure to the selection and sequencing of systemic therapy for newly diagnosed and relapsed/refractory CLL.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for patients with CLL to support quality of life and continuation of therapy.
  • Appreciate available data with and consider the potential clinical roles of novel agents and regimens that may soon provide patients with treatment options beyond the initial indications.
  • Recall available and emerging data with other investigational agents, regimens and immunotherapeutic strategies currently in Phase III testing for CLL, and, where applicable, refer eligible patients for clinical trial participation or expanded access programs.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with CLL to optimize clinical and quality-of-life outcomes.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CME/CNE planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AbbVie Inc, Genentech, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC and Pharmacyclics LLC, an AbbVie Company.

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room: 
Grand Ballroom E-K (Lobby Level)

The Anaheim Marriott is the headquarters hotel for the 2019 ONS Congress and is conveniently located near the Anaheim Convention Center (0.2 miles).


Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 4 — Chronic Lymphocytic Leukemia. Onsite registration will be open starting at 11:45 AM on Thursday, April 11, 2019. If you are interested in standing by for seating (day of the program), please visit our onsite registration desk located outside the Grand Ballroom (Lobby Level) at the Anaheim Marriott hotel (700 West Convention Way, Anaheim, CA 92802). You may arrive up to 45 minutes before the program start time and receive a standby ticket.

If seats become available for the program, we will accept standby registration on a first come, first served basis prioritized for oncology nurses treating patients. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at or call (800) 233-6153.